QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-neutral-on-spruce-biosciences

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spruce Biosciences (NASDAQ:SPRB) with a Neutral.

 rbc-capital-reiterates-sector-perform-on-spruce-biosciences-maintains-2-price-target

RBC Capital analyst Gregory Renza reiterates Spruce Biosciences (NASDAQ:SPRB) with a Sector Perform and maintains $2 price t...

 spruce-biosciences-q2-eps-022-beats-030-estimate-sales-161m-beat-150m-estimate

Spruce Biosciences (NASDAQ:SPRB) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(...

 oppenheimer-maintains-outperform-on-spruce-biosciences-lowers-price-target-to-3

Oppenheimer analyst Hartaj Singh maintains Spruce Biosciences (NASDAQ:SPRB) with a Outperform and lowers the price target fr...

 hc-wainwright--co-reiterates-neutral-on-spruce-biosciences

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spruce Biosciences (NASDAQ:SPRB) with a Neutral.

 nano-cap-spruce-biosciences-collaborates-with-hmnc-brain-health-to-develop-treatment-for-major-depressive-disorder

Spruce Biosciences collaborates with HMNC Brain Health to advance tildacerfont, a precision therapeutic for major depressive di...

 spruce-biosciences-presented-results-from-phase-2-power-study-of-tildacerfont-for-polycystic-ovary-syndrome-at-the-2024-annual-meeting-of-the-endocrine-society

Significant Reduction in Dehydroepiandrosterone Sulfate (DHEAS) Versus Placebo Observed in Women with Elevated DHEAS Levels a...

 hc-wainwright--co-reiterates-neutral-on-spruce-biosciences

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spruce Biosciences (NASDAQ:SPRB) with a Neutral.

 spruce-biosciences-q1-eps-028-beats-029-estimate-sales-202m-beat-116m-estimate

Spruce Biosciences (NASDAQ:SPRB) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(...

 spruce-biosciences-hormone-treatment-stumbles-in-trials-prompts-stock-freefall

Spruce Biosciences faces setbacks as tildacerfont trials fail primary endpoints, raising concerns about drug efficacy and compl...

 dow-dips-over-100-points-dicks-sporting-goods-earnings-top-views

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow...

 why-limbach-holdings-shares-are-trading-lower-by-around-15-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarte...

 crude-oil-moves-higher-dollar-general-posts-upbeat-earnings

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow tr...

 rbc-capital-downgrades-spruce-biosciences-to-sector-perform-lowers-price-target-to-2

RBC Capital analyst Gregory Renza downgrades Spruce Biosciences (NASDAQ:SPRB) from Outperform to Sector Perform and lowers t...

 us-stocks-higher-producer-prices-rise-06-in-february

U.S. stocks traded higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow trad...

 hc-wainwright--co-downgrades-spruce-biosciences-to-neutral

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Spruce Biosciences (NASDAQ:SPRB) from Buy to Neutral.

 why-is-rare-endocrine-disorder-focused-spruce-biosciences-stock-plummeting-on-thursday

Spruce Biosciences' latest CAH studies: CAHmelia-203 & CAHptain-205. Discover insights on tildacerfont's efficacy, ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION